Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hollenbaugh
Diane Hollenbaugh, Mountain View, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100158911 | Compositions and Methods of Treating Disease with FGFR Fusion Proteins - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 06-24-2010 |
| 20110033465 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS - The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9. | 02-10-2011 |
Diane L. Hollenbaugh, Seattle, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20090186037 | METHODS FOR INHIBITING AN IMMUNE RESPONSE BY BLOCKING THE GP39/CD40 AND CTLA4/CD28/B7 PATHWAYS AND COMPOSITIONS FOR USE THEREWITH - The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection. | 07-23-2009 |
William Hollenbaugh, Rochester, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20080268364 | Methods for making customized black toners - According to embodiments illustrated herein, there is provided a black toner having a resin, an optional additive, and at least two or more colored pigments, and the at least two or more colored pigments are selected from the group consisting of a blue pigment, a green pigment, a red pigment, a magenta pigment, a cyan pigment, a yellow pigment, a white pigment, and mixtures thereof, and the black toner has a calorimetric value L* of about less than 30. | 10-30-2008 |
William H. Hollenbaugh, Rochester, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20080220362 | TONER COMPOSITIONS HAVING IMPROVED FUSING PROPERTIES - Image recording device comprising a development system including toner particles comprising a gel latex, a high Tg latex, a wax, and a colorant, and a fuser member, such as a fluoropolymer coated fuser member, which produces images having improved document offset, vinyl offset and half-tone rub properties. | 09-11-2008 |